Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Maintains $11 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price target.
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price target.